In-Depth Analysis of the Locally Advanced Pancreatic Cancer Market: Growth Opportunities, Key Trends, and Forecast 2025-2034

What combination of drivers is leading to accelerated growth in the locally advanced pancreatic cancer market?
The rise in tobacco consumption is expected to contribute to the growth of the locally advanced pancreatic cancer market in the coming years. Tobacco, derived from the leaves of the plant and used in products like cigarettes and cigars, contains nicotine, which is addictive and associated with serious health issues such as cancer and heart disease. The increase in tobacco use is driven by factors such as easy access, affordability, marketing strategies, social acceptance in certain areas, and stress-induced smoking. Tobacco consumption is a major risk factor for developing locally advanced pancreatic cancer, as it leads to a higher incidence of pancreatic malignancies. For example, in January 2024, the Global Action to End Smoking, a US-based nonprofit focused on eliminating smoking, reported that in 2022, about 62.9 million adults in the U.S. used tobacco, making it the 4th highest globally and the leading country in the Americas. Additionally, around 11.5% of U.S. adults (28.3 million) smoked cigarettes, with male smokers (13.1%) surpassing female smokers (10.1%). Therefore, the increase in tobacco consumption is driving the growth of the locally advanced pancreatic cancer market.

Get Your Locally Advanced Pancreatic Cancer Market Report Here:
https://www.thebusinessresearchcompany.com/report/locally-advanced-pancreatic-cancer-global-market-report

What is the projected compound annual growth rate (CAGR) of the locally advanced pancreatic cancer market from 2025 to 2034, and what factors influence it?
The locally advanced pancreatic cancer market has expanded rapidly, growing from $0.95 billion in 2024 to $1.05 billion in 2025 at a CAGR of 10.9%. Growth is attributed to rising awareness of pancreatic cancer, improved chemotherapy regimens, greater use of targeted therapies, a higher incidence of pancreatic cancer, development of combination treatment protocols, and enhanced supportive care options.

The locally advanced pancreatic cancer market is set for rapid expansion, reaching $1.57 billion by 2029 at a CAGR of 10.5%. The anticipated growth is attributed to greater awareness about pancreatic cancer, enhanced chemotherapy regimens, increased use of targeted therapies, a rising incidence of the disease, advancements in combination treatment strategies, and improved supportive care measures. Major trends expected in this market include breakthroughs in immunotherapy, development of targeted treatment options, precision radiation techniques, enhancements in diagnostic imaging, adoption of minimally invasive surgery, incorporation of artificial intelligence in treatment planning, and further innovations in combination therapy.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

How are the latest trends influencing the growth of the locally advanced pancreatic cancer market?
In the locally advanced pancreatic cancer market, companies are focusing on developing orphan drugs to improve treatment options and patient outcomes for this aggressive disease. Orphan drugs are specifically designed to treat rare diseases and often receive incentives such as tax reductions and market exclusivity. For example, in January 2025, Actuate Therapeutics Inc., a US-based biopharmaceutical company, announced that its Elraglusib, a GSK-3ß inhibitor, received Orphan Drug Designation from the FDA and EMA for treating pancreatic ductal adenocarcinoma (PDAC), a form of locally advanced pancreatic cancer. Elraglusib showed significant clinical improvements in metastatic PDAC patients during Phase 2 trials, offering hope for a new therapeutic approach to this difficult-to-treat cancer.

What are the major segments of the locally advanced pancreatic cancer market and their role in driving growth?
The locally advanced pancreatic cancer market covered in this report is segmented -

1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Surgery
2) By Route Of Administration: Oral, Injectables, Other Route Of Administrations
3) By End-User: Hospital, Specialty Clinics, Research Institutions, Other End-Users

Subsegments:
1) By Chemotherapy: Gemcitabine-based Chemotherapy, FOLFIRINOX Chemotherapy
2) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines
3) By Radiation Therapy: External Beam Radiation Therapy, Stereotactic Body Radiation Therapy (SBRT)
4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure), Distal Pancreatectomy, Total Pancreatectomy

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21214

Which regions are key players in the growth of the locally advanced pancreatic cancer market?
North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Who are the key firms paving the way for growth in the locally advanced pancreatic cancer market?
Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp

What Is Covered In The Locally Advanced Pancreatic Cancer Global Market Report?

•Market Size Forecast: Examine the locally advanced pancreatic cancer market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the locally advanced pancreatic cancer market for a structured understanding.
•Key Players Overview: Analyze major players in the locally advanced pancreatic cancer market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the locally advanced pancreatic cancer market.
•Segment Contributions: Evaluate how different segments drive overall growth in the locally advanced pancreatic cancer market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the locally advanced pancreatic cancer market.
•Industry Challenges: Identify potential risks and obstacles affecting the locally advanced pancreatic cancer market.
•Competitive Landscape: Review strategic developments in the locally advanced pancreatic cancer market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.